Comparative Pharmacology
Head-to-head clinical analysis: MERCAPTOPURINE versus XATMEP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MERCAPTOPURINE versus XATMEP.
MERCAPTOPURINE vs XATMEP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mercaptopurine is a prodrug that is converted to 6-thioguanine nucleotides, which inhibit de novo purine synthesis and DNA replication by incorporating into DNA and RNA. It also inhibits purine nucleotide interconversions via feedback inhibition of amidophosphoribosyltransferase.
Methotrexate is a folate analog that inhibits dihydrofolate reductase, blocking the synthesis of tetrahydrofolate and thereby inhibiting DNA synthesis and cell proliferation. It also has immunosuppressive and anti-inflammatory effects through inhibition of purine metabolism and adenosine accumulation.
1.5 to 2.5 mg/kg orally once daily; maintenance 1.5 to 2.5 mg/kg orally once daily.
Methotrexate 10 mg orally once weekly; maximum 25 mg per week.
None Documented
None Documented
Clinical Note
moderateMercaptopurine + Digoxin
"Mercaptopurine may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateMercaptopurine + Digitoxin
"Mercaptopurine may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateMercaptopurine + Deslanoside
"Mercaptopurine may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateMercaptopurine + Acetyldigitoxin
"Mercaptopurine may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life: 1.5-3 hours (variable); for active metabolites (e.g., 6-thioguanine nucleotides) half-life is 5-7 days, which correlates with myelosuppression.
The terminal elimination half-life of methotrexate is approximately 3-10 hours for low doses (<50 mg/m²) and 8-15 hours for high doses (≥500 mg/m²). Prolonged half-life (>24 hours) is associated with renal impairment and drug accumulation, increasing toxicity risk.
Renal: 20-30% as unchanged drug; biliary/fecal: minor; extensive hepatic metabolism to active and inactive metabolites.
Methotrexate is primarily eliminated renally via glomerular filtration and active tubular secretion. Approximately 80-90% of the dose is excreted unchanged in urine within 24 hours. Fecal excretion is minimal (<10%), with biliary elimination accounting for a small fraction.
Category D/X
Category C
Antimetabolite
Antimetabolite